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Over the past few years, increasing interest in the role of autoantibodies against myelin oligodendrocyte
glycoprotein (MOG-abs) as a new candidate biomarker in demyelinating central nervous system diseases
has arisen. MOG-abs have now consistently been identified in a variety of demyelinating syndromes,
with a predominance in paediatric patients. The clinical spectrum of these MOG-ab-associated disorders
(MOGAD) is still expanding and differs between paediatric and adult patients. This first part of the
Paediatric European Collaborative Consensus emphasises the diversity in clinical phenotypes associated
with MOG-abs in paediatric patients and discusses these associated clinical phenotypes in detail. Typical
MOGAD presentations consist of demyelinating syndromes, including acute disseminated encephalo-
myelitis (ADEM) in younger, and optic neuritis (ON) and/or transverse myelitis (TM) in older children. A
proportion of patients experience a relapsing disease course, presenting as ADEM followed by one or
multiple episode(s) of ON (ADEM-ON), multiphasic disseminated encephalomyelitis (MDEM), relapsing
ON (RON) or relapsing neuromyelitis optica spectrum disorders (NMOSD)-like syndromes. More recently,
the disease spectrum has been expanded with clinical and radiological phenotypes including
encephalitis-like, leukodystrophy-like, and other non-classifiable presentations. This review concludes
with recommendations following expert consensus on serologic testing for MOG-abs in paediatric pa-
tients, the presence of which has consequences for long-term monitoring, relapse risk, treatments, and
for counselling of patient and families. Furthermore, we propose a clinical classification of paediatric
MOGAD with clinical definitions and key features. These are operational and need to be tested, however
essential for future paediatric MOGAD studies.
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society. This is
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ADS acquired demyelinating syndrome
ADEM acute disseminated encephalomyelitis
ADEM-ON ADEM followed by monophasic or recurrent ON
AE autoimmune encephalitis
AQP4-ab aquaporin-4 antibody
CNS central nervous system
CRION chronic relapsing inflammatory optic neuropathy
(LE)TM (longitudinally extensive) transverse myelitis
MOG-ab myelin oligodendrocyte glycoprotein antibody
MOGAD MOG-antibody-associated disorders
MOG-ON MOG-ab-associated ON
MOG-TM MOG-ab-associated TM
MDEM multiphasic disseminated encephalomyelitis
NMOSD neuromyelitis optica spectrum disorders
OCT optical coherence tomography
ON optic neuritis
RNFL retinal nerve fibre layer
RON relapsing ON1. Introduction
Paediatric acquired demyelinating syndromes (ADS) consist of a
broad spectrum of immune-mediated demyelinating diseases of
the central nervous system (CNS), including acute disseminated
encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis
(TM), neuromyelitis optica spectrum disorders (NMOSD) and
multiple sclerosis (MS). Diagnosis of the specific phenotype at
initial presentation can be challenging, as the situation frequently
evolves over time [1e4]. The discovery of pathogenic serum auto-
antibodies targeted against aquaporin-4 (AQP4-abs) in 20043
enables their use as a diagnostic marker for AQP4-ab-positive
NMOSD [5]. Over the past few years, there has been increasing
interest in the role of autoantibodies against myelin oligodendro-
cyte glycoprotein (MOG-abs) as a candidate biomarker in demye-
linating CNS diseases [6,7]. These antibodies target MOG, which is
expressed exclusively on the outer surface of the myelin sheath and
plasma membrane of oligodendrocytes [8,9]. Although MOG rep-
resents only a minor component of myelin (0.5%), it is a likely target
for autoantibodies in a demyelinating disease due to its CNS spec-
ificity and highly immunogenic location [6,9]. While initially MOG-
abs were thought to be a possible biomarker for MS, following
improvements in assay design [10], multiple studies have estab-
lished that MOG-abs are present only in a small proportion of MS
patients [11e13]. Indeed, nowadays it is widely accepted that the
presence of MOG-abs indicates a different disease and argues
against an MS diagnosis [12,14].
MOG-abs have consistently been identified in an expanding
spectrum of demyelinating syndromes, with predominance and
increased heterogeneity in paediatric patients [15e17]. There-
fore, this first part of the Paediatric European Collaborative
Consensus will focus on the classification of the different pae-
diatric clinical phenotypes within MOG-ab-associated disorders
(MOGAD). Furthermore, consensus recommendations on sero-
logic testing for MOG-abs in the paediatric population are
included as guidance for clinicians in daily practice, as early
diagnosis is relevant for accurate disease monitoring and treat-
ment strategies.2. Frequency and general characteristics of paediatric MOGAD
2.1. Incidence and prevalence of MOG-abs in paediatric ADS and
frequency of MOGAD presentations
MOGAD are rare, with a higher incidence in paediatric
compared to adult patients. A recent Dutch study reported a mean
Fig. 1. ADS presenting phenotype, divided for MOG-ab-positive and negative patients
[11e14,17e23].
ADEM ¼ acute disseminated encephalomyelitis, ADS ¼ acquired demyelinating syn-
drome, MOG-ab ¼ myelin oligodendrocyte glycoprotein antibody, ON ¼ optic neuritis,
TM ¼ transverse myelitis.
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compared to 0.13 per 100.000 adults per year (95% CI 0.08e0.19)
[17]. A recent review of 61 studies also described a higher preva-
lence of MOG-abs in paediatric (40%) compared to mixed (29%) and
adult (22%) cohorts [16].
Various studies have determined the prevalence of MOG-abs
within paediatric ADS [11e14,17e24], using the reliable live cell-
based assay (CBA) [10]. According to pooled data of these 11
studies, MOG-abs are present in one third of all paediatric patients
with ADS (34%; Fig. 1). Focusing on the different presenting phe-
notypes, these studies have shown that MOG-abs are predomi-
nantly found in patients presenting with ADEM (53%, range
33e65%), ON (40%, range 10e67%), and TM (18%, range 0e35%). An
NMOSD-like phenotype with combination of ON and TM as pre-
senting symptom is only reported in a limited number of ADS pa-
tients, with MOG-abs detected in 40% of these patients, however
varying from 25 to 100% between studies [11,13,14,21,23].
The different clinical presentations of paediatric MOGAD at
disease onset are shown in Fig. 2 [11e14,17,20e27]. Summarising
data of these 13 studies, themost common include ADEM (46%), ON
(30%), TM (11%) and NMOSD-like phenotype with simultaneous ON
and TM (4%). Together these clinical presentations comprise
already more than 90% of all phenotypes encompassed by paedi-
atric MOGAD and will be discussed in detail below.Fig. 2. Presenting clinical phenotypes within the paediatric MOGAD [11e13,17,20e27].
ADEM ¼ acute disseminated encephalomyelitis, MOGAD ¼ MOG-antibody-associated
disorders, ON ¼ optic neuritis, TM ¼ transverse myelitis.
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2.2. General characteristics of paediatric MOGAD and age
dependency
Themajority of patients in studies withMOGAD are of Caucasian
descent [12,17,28,29], which most likely represents population
rather than a true ethnicity bias as seen in AQP4-ab-positive dis-
ease [30]. Boys and girls are almost equally distributed, with only a
slight preponderance of females in older children
[11e14,17,20,23,26,28,29,31], in contrast to the female preponder-
ance in both MS [32] and AQP4-ab-positive NMOSD [30,33].
Comparing paediatric ADS patients with and without MOG-abs,
paediatric MOGAD patients are younger [11,13,14,20,28]. This dif-
ference may be due to the high number of ADEM patients within
the MOGAD, who are generally the youngest among all ADS pa-
tients, and therefore could skew the age distribution. The fact that
paediatric ADEM, ON and NMOSD patients with and without MOG-
abs do not differ in age, supports this [31,33e37].
The presenting clinical phenotype of MOG-ab-positive patients
appears to be strongly dependent on age at onset, with brain
involvement seen more commonly in younger children (including
ADEM and ADEM-like phenotypes), and an opticospinal phenotype
(including ON and/or TM or brainstem involvement) more often in
older children [13,25,28], and adult patients [17,38e41]. The tran-
sition of this bimodal distribution seems to be around the age of
nine [16]. As MOG is only expressed during late stages of myeli-
nation, it is thought to play a role inmaturation of the CNS [42]. This
age dependency of presenting clinical phenotype may represent a
changing MOG expression during different stages of brain devel-
opment and CNS maturation in childhood [7,25,28].
3. Typical clinical phenotypes of paediatric MOGAD
3.1. Acute disseminated encephalomyelitis (ADEM)
The heterogeneous clinical syndrome ADEM predominantly
occurs in early childhood and is characterised by encephalopathy,
polyfocal neurological deficits and typical magnetic resonance
imaging (MRI) abnormalities, which can fluctuate during the acute
phase (up to three months after disease onset) [2,43,44]. The
presence of encephalopathy, defined by the International Paediatric
Multiple Sclerosis Society Group (IPMSSG) as an altered con-
sciousness or behavioural changes, both not explained by fever, is
required for a diagnosis of ADEM [2]. This requirement is essential,
because it distinguishes ADEM from other ADS.
ADEM is the most frequent type of paediatric MOGAD, but there
is only one study comparing paediatric ADEM patients with and
without MOG-abs. This study included 19 MOG-ab-positive and 14
negative patients [31]. Almost all these ADEM patients presented
with altered consciousness due to encephalopathy, which was not
different between MOG-ab-positive and negative patients. How-
ever, ADEM patients with MOG-abs presented less frequently with
emotional or behavioural problems as representation of encepha-
lopathy, compared to patients without MOG-abs (5% vs. 43%).
Interestingly, besides a higher number of white blood cells in ce-
rebrospinal fluid (CSF) in MOG-ab-positive patients, the remaining
demographic and clinical characteristics at onset of disease,
including age, sex ratio and other clinical symptoms, could not
discriminate ADEM patients with MOG-abs from those without.
Based on the MRI comparison however, the MOG-ab-positive pa-
tients more often had spinal cord involvement compared to MOG-
ab-negative patients (93% vs. 33%). Remarkably, only 62% of the
MOG-ab-positive patients with spinal involvement suffered from
spinal symptoms, compared to 100% of the MOG-ab-negative pa-
tients with spinal cord involvement [32].
Although ADEM patients generally have a favourable long-term
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risk of long-term cognitive impairment [45,46,123], and a higher
risk of post-ADEM epilepsy in MOG-ab-positive compared to MOG-
ab-negative patients [47]. While ADEM patients typically have a
monophasic disease course, relapses can occur in the MOG-ab-
positive ADEM patients [31]. These relapsing clinical phenotypes
after ADEM are discussed later.
In conclusion, up to 50% of paediatric ADEM patients are MOG-
ab positive and ADEM is the most common presenting clinical
phenotype of paediatric MOGAD. Although there are a few clinical
and radiological differences between ADEM patients with and
without MOG-abs, it still is not possible to distinguish these pa-
tients at onset of disease based on these features alone.
3.2. Optic neuritis (ON)
The inflammation of the optic nerve(s) in ON causes unilateral
or bilateral visual problems, typically including visual loss, central
scotoma or reduced visual fields and impaired colour vision, and is
often accompanied with painful eye movements [32]. Paediatric
MOG-ab-positive patients presenting with ON predominantly are
adolescents between 13 and 18 years of age [13,25,28,47]. In pa-
tients with ON as clinically isolated syndrome, paediatric ON has
different clinical features than ON in adults (most likely repre-
senting MS patients), regarding severity, bilateral vs. unilateral, and
presence of disc oedema [48]. Studies exclusively analysing pae-
diatric patients withMOG-ab-associated ON (MOG-ON) are limited.
The only three paediatric studies available, one European and
two large Asian cohorts, showed that the majority of the paediatric
MOG-ON patients had severe visual loss at onset, with a visual
acuity (VA) of 0.1 at nadir, which is comparable to the vision loss
at nadir of paediatric AQP4-ab-positive, double seronegative (i.e.
MOG-ab and AQP4-ab-negative) and MS patients with ON
[35,37,49]. However, after six months follow-up the MOG-ab-
positive patients made a good recovery with a functional VA of
0.5 in 98% of patients [36], and0.8 in 89% of patients [35], which
is significantly better than AQP4-ab-positive, but comparable with
double seronegative and MS patients with ON [35,37,49].
Simultaneous bilateral optic nerve involvement has been re-
ported in most studies in more than 50% of paediatric MOG-ab-
positive patients [20,35e37,49], although lower numbers have
also been reported (29e38%) [17,23,33], and mixed paediatric and
adult cohorts showed that bilateral involvement is more often seen
in adult MOG-ab-positive patients [17,40,41]. Such bilateral
involvement is atypical for MS [50]. In addition, a recent study
showed that 73% of paediatric patients presenting with bilateral ON
had MOG-abs [51]. Furthermore, a substantial proportion of pae-
diatric MOG-ON patients presented with prominent optic disc
oedema (60e90%), due to anterior involvement of the optic nerve
in these patients [35,37,41]. Unlike in adults, disc oedema did not
distinguish MOG-ab-positive from AQP4-ab-positive and double
seronegative paediatric ON patients [35,37]. Additionally, besides
the anterior optic nerve inflammation, MRI images of MOG-ON
showed high rates of longitudinal involvement of the optic nerve
in mixed paediatric and adults cohorts (90%), with relative sparing
of the chiasm and optic tracts [41,48,50e53,124]. The latter being
important since this is different fromON associated with AQP4-abs,
where patients more often have chiasmal and optic tract involve-
ment [50]. Additionally, perineural enhancement and inflammation
of soft orbital tissues on MRI has been described in up to 50% of
(mainly) adult patients presenting with MOG-ON [54e58], dis-
tinguishing MOG-ab-positive from AQP4-ab-positive and MS pa-
tients with ON [56,58]. This phenotype can be referred to as “ON
plus phenotype”.
A proportion of these ON patients will experience further5
relapses. The relapsing clinical phenotypes following ON are dis-
cussed later in more detail. Importantly, although in general the
functional VA of MOG-ON patients recovers well, optical coherence
tomography (OCT) scans showed signs of severe axonal damage,
which was as severe as observed in AQP4-ab-positive patients
[35,49,59], and was not or only partly correlated to the number of
ON episodes [35,49,123].
In conclusion, paediatric MOG-ON patients are mainly adoles-
cents who have severe visual loss at onset of disease, often with
optic disc oedema and in about half of them simultaneous bilateral
ON. These patients usually have a good functional visual recovery,
although OCT scans reveal indication of permanent axonal damage.3.3. (Longitudinally extensive) transverse myelitis ((LE)TM)
Patients with (LE)TM can present with motor and sensory def-
icits, which are often bilateral and include a sensory level, and/or
bladder and bowel dysfunction, progressing within hours to days
[32]. Due to the rarity of MOG-ab-associated TM (MOG-TM) in
childhood, literature on this specific MOGAD phenotype in paedi-
atric patients is sparse, without any studies comparing paediatric
TM patients with and without MOG-abs.
However, one retrospective study included 54 patients with
MOG-TM patients, among them 16 paediatric patients (30%), with
isolated TM (54%) or TM as part of a multifocal disease presentation
with ADEM (17%) or ON (6%) [60]. Similar to the ON patients, almost
all TM patients had a severe disease at onset including prominent
motor and sensory deficits, with one third of patients being
wheelchair bound. Furthermore, 85% of these patients presented
with neurological bowel and bladder dysfunction, and additionally
54% of male patients with erectile dysfunction, probably attribut-
able to the often longitudinally extensive lesion with frequent
conus involvement observed on MRI in these patients (41%). This
conus involvement has also been demonstrated in 37% of all pae-
diatric MOG-ab-positive patients presenting with spinal cord le-
sions [24].While LETM is also characteristic for AQP4-ab-associated
TM, conus involvement is more typical for MOG-TM [33,60e62].
Interestingly, 19% of patients of the above described retrospective
study presented with a flaccid areflexia, which can be explained by
the predilection for the central grey matter in MOG-TM, also typical
for AQP4-ab-associated TM, but atypical for MS-associated TM [60].
Regardless of the disease severity at onset, most of these MOG-
TM patients showed a good motor recovery [60], which may be
better than the recovery in TM patients without MOG-abs, as pre-
vious paediatric TM cohorts with unknown MOG-ab serostatus
reported worse outcomes [63,64]. However, bowel, bladder and/or
erectile residual symptoms are common [60,123]. A proportion of
MOG-TM patients have recurrent episodes during follow-up,
described in around 17% of adult [27,39], and 0e14% of paediatric
MOG-TM patients [14,22,33]. Furthermore, patients presenting
with MOG-TM may have other relapses during follow-up, e.g. ON,
extending the MOGAD phenotype to an NMOSD-like phenotype,
also reported in around 14% of paediatric patients [33].
In conclusion, isolated TM only covers a small part of the pae-
diatric MOGAD. MOG-TM often causes severe deficits at onset,
including motor, sensory, and bowel, bladder and/or erectile
impairment. Patients often have a LETM, in contrast to MS patients.
Moreover, conus involvement can distinguish them from AQP4-ab-
positive patients. Although patients make a good motor recovery,
bowel, bladder and/or erectile residual symptoms are common and
important features to discuss with the patient and to monitor
during follow-up, besides the long-term monitoring for potential
relapses.
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phenotype
Neuromyelitis optica (NMO) initially was characterised by
recurrent uni- or bilateral ON and (LE)TM. In 2015, the spectrum
was broadened by inclusion of brainstem syndromes and limited
forms of NMO, altogether referred to as NMO spectrum disorders
(NMOSD) [4,65]. Although the presence of AQP4-abswas added as a
supportive diagnostic criterion, these antibodies are rare in child-
hood, only found in 3e6% of ADS [13,22] and 11% of NMOSD pa-
tients [33]. In contrast, MOG-abs are found in one third of
paediatric ADS and in 56% of paediatric patients with an NMOSD-
like phenotype [33].
As described above, ON and (LE)TM can occur either as isolated
clinical MOGAD phenotypes, or simultaneously, representing an
NMOSD-like phenotype at onset of disease. Interestingly, in a study
analysing paediatric NMOSD(-like) patients, none of the AQP4-ab-
positive patients had concomitant ON and (LE)TM, in contrast to
85.7% of MOG-ab-positive patients [33]. This simultaneous
phenotype has been observed in adult MOG-ab-positive patients in
lower percentages (around 40%) [62,66,67], but still was a
discriminative feature from AQP4-ab-positive NMOSD [66].
Since broadening NMO to NMOSD, brainstem involvement with
inflammation of the area postrema is included as feature of AQP4-
ab-positive NMOSD [65]. Area postrema syndrome (APS) causes
intractable nausea, vomiting and/or unexplained hiccups, and is
thought to be highly specific for AQP4-abs [68]. However, adult
studies with MOG-ab-positive patients also reported brainstem
involvement in 10e30% [18,70], e.g. with cranial nerve deficits,
ataxia, respiratory insufficiency, and also nausea and vomiting as
clinical symptoms [70]. In contrast, in paediatric MOG-ab-positive
patients, isolated brainstem syndromes or brainstem involvement
ever during disease course were only rarely observed (0e3% and
0e4%, respectively) [17,33], and evidently more often seen in the
paediatric AQP4-ab-positive patients (20% and 60%, respectively)
[33]. Lastly, as described above, both AQP4-ab and MOG-ab-
positive patients can experience symptoms of APS (nausea, vom-
iting and/or hiccups), but in MOG-ab-positive patients these
symptoms rarely seem to be attributed to inflammation of the area
postrema, as seen in AQP4-ab-positive NMOSD, but may be due to
disruption of anatomical connections to the vomiting centre [70].
Therefore, pure APS with inflammation of the area postrema re-
mains a typical feature for AQP4-ab-positive NMOSD.Table 1
Differences between paediatric AQP4-ab-positive NMOSD and MOG-ab-associated NMO
NMOSD-like phenotypes
MOG-abþ
Demographics More often in paediatric patients
Equal distribution boys/girls
No association with other AID
Clinical
phenotypes
*ON * Bilateral, longitudinally extensive with anterior involvement (disc
*TM * LETM with conus involvement
*NMOSD(-like) * Often simultaneous ON and TM, area postrema syndrome is rare
Severity at onset Severe
Recovery Promptly after steroids and often completely, except for axonal dama
problems (TM)
Disease course More often monophasic, but relapses are possible
AID¼ autoimmune disease, AQP4-ab¼ aquaporin-4 antibody, LETM¼ longitudinally exte
NMOSD ¼ neuromyelitis optica spectrum disorders, OCT ¼ optical coherence tomograph
a Discriminative feature for MOG-abs and AQP4-abs in mixed paediatric and adult stu
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Despite clinical overlap between AQP4-ab-positive NMOSD and
MOG-ab-associated NMOSD-like phenotypes, differences exist as
summarised in Table 1. Importantly, the underlying immunological
disease mechanisms of both antibody-associated diseases is
different, with AQP4-abs targeting astrocytes and MOG-abs tar-
geting oligodendrocytes, resulting in astrocytopathy and oligo-
dendrocytopathy, respectively [71e73]. Additionally, differences in
human leukocyte antigen association are found, suggestive of a
distinctive underlying immunogenetic background [74]. There is an
ongoing debate about the nosology of these disorders [75,76],
although many argue for a separation of MOGAD from AQP4-ab-
positive NMOSD [15,33,34,77e80].
In conclusion, AQP4-ab-positive NMOSD is rare in paediatric
patients, and NMOSD-like phenotypes with MOG-abs are more
common [81]. Typical for MOGAD is simultaneous ON and TM.
While adult patients may have brainstem involvement, this is rare
for paediatric patients. An area postrema syndrome attributable to
inflammation in the area postrema is rare and remains a typical
feature of AQP4-ab-positive NMOSD.
4. Relapsing phenotypes
The frequency of relapses among all paediatric MOG-ab-positive
patients ranges widely between studies, because of e.g. differences
in follow-up time, study design (retro- vs. prospective) and patient
selection (nationwide coverage vs. secondary academic centres).
Recent studies, with longer follow-up duration, have revealed
increasing evidence for a multiphasic disease course in a subset of
MOG-ab-positive patients [13,14,82]. Patients who remain sero-
positive during follow-up appear at higher risk for relapse
compared to the patients who convert to a seronegative status (38%
vs. 13%, respectively) [14]. Additionally, older age has been found to
be strongly associated with a relapsing disease course [14,123].
In 2018, the European Paediatric Demyelinating Disease Con-
sortium studied 102 MOG-ab-positive patients with a relapsing
disease course [83]. Median follow-up was five years. This cohort
included multiphasic disseminated encephalomyelitis (MDEM;
20%), ADEM followed by one or more ON episode(s) (ADEM-ON;
20%), relapsing ON (RON; 18%) and relapsing NMOSD (43%). Inter-
estingly, the same age dependency of clinical phenotype was
observed for the relapses, with MDEM and ADEM-ON in the
younger, and RON and NMOSD in the older patients, again with the
division between these phenotypes around the age of nine.SD-like phenotypes.
AQP4-abþ
Rare in paediatric patients
Predominance in girls
Association with other AID
oedemaa) * Longitudinally extensive with chiasma/optic
tract involvement
* LETM with cervico-thoracic spinal cord
involvement
* Area postrema syndrome, isolated brainstem
syndrome
Severe
ge on OCT (ON) and bowel/bladder High risk for poor recovery
Relapsing
nsive transverse myelitis, MOG-ab¼myelin oligodendrocyte glycoprotein antibody,
y, ON ¼ optic neuritis, TM ¼ transverse myelitis, þ ¼ positive, e ¼ negative.
dies, but not in paediatric studies exclusively.
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ADEM, whilst usually monophasic, can present as a relapsing
form, known as MDEM [2]. Almost all MDEM patients are MOG-ab
positive [11,13,14,21,31]. Importantly, clinical symptoms and
radiologic features can fluctuate during the acute phase of ADEM
(up to three months) [2], mainly during weaning off immuno-
modulatory treatment. Therefore, during this acute ADEM period it
is important to be aware of the possibility of a “flare-up”, which
does not reflect a true relapse [125]. A relapse was defined by the
consensus group as a new clinical episode accompanied by radio-
logical evidence depending on the subtype of MOGAD, appearing at
least one month subsequently to the last acute attack. On the
contrary, a “flare-up” was defined by the consensus group as re-
occurrence of symptoms within one month (and up to three
months in ADEM patients) after start of acute treatment and not
meeting definition of a relapse.
The first study describing multiple MDEM patients was pub-
lished in 2016 [84]. In total, only eight MDEM patients were iden-
tified from 295 paediatric ADS patients including 59 ADEM
patients, and all eight were MOG-ab-positive. These numbers are
comparable to the reported number of MDEM patients in other
paediatric ADS cohorts, in whom almost all had positive MOG-abs
[11,13,14,22,30]. Remarkable is the heterogeneity between MDEM
patients, observed in the initial eight patients [84], but also in the
20 MOG-ab-positive MDEM patients identified from the European
Paediatric Demyelinating Disease Consortium [83]. Although
IPMSSG criteria for MDEM are limited to only two ADEM episodes
[2], studies with MOG-ab-positive MDEM patients have shown that
these patients may have only one relapse, but can also have mul-
tiple, withmore than ten documented in certain cases [83,84]. Most
patients had a new attack within two years after onset, but new
attacks also occurred years later. In these cohorts with MDEM pa-
tients, 25e50% of patients had a good recovery, but the remaining
patients had mild to moderate impairment, including cognitive
deficits, motor deficits or seizures [83,84]. Every new relapse with
new brain demyelination might increase the risk of secondary
neuroaxonal injury, and consequently, risk of poor outcome might
depend on number of relapses [42]. However, this hypothesis has
not been investigated systematically in paediatric patients yet.
4.2. ADEM-ON
A subgroup of children with initial ADEM presentation continue
to have demyelinating episode(s) limited to the optic nerve (ADEM-
ON) [83]. As for MDEM, during the acute phase of ADEM (up to
three months) the possibility of a “flare-up”, instead of a true
relapse, should be considered [125], as optic nerve involvement can
also occur during the acute phase of ADEM [2,31].
The majority of these ADEM-ON patients are MOG-ab positive
[11,13,22,31,85,86]. Like MDEM, this ADEM-ON phenotype is rare
and characteristics of these patients have only been described
previously in detail in seven patients from Germany [84] and more
recently in 20 patients from the European Paediatric Demyelinating
Disease Consortium [86]. The heterogeneity among ADEM-ON pa-
tients is comparable to MDEM patients; the number of relapses
ranged from one to nine per patient, and the interval between re-
lapses ranged from three months to even 20 years in one patient
[85,86]. Furthermore, relapses occurred in patients after a long
steady period without treatment, but also in patients on treatment
[86]. In a high proportion of patients (60e70%), visual residual
deficits were reported [85,85], which were not related to the
number of relapses, at least not in this small sample size [87].
Importantly, in the ADEM patients with further relapses, a shorter
time to first relapse [86] as well as a persistent MOG-ab positivity7
during follow-up [34] were found to both increase the risk of
(further) relapses, the latter arguing for longitudinal MOG-ab
testing for prediction of relapse risk [10,123].
4.3. Relapsing ON (RON)
As the majority of adult patients already present with ON, RON
is the most frequent relapsing phenotype in adulthood [34,41],
while in childhood, an ON relapse can result in ADEM-ON, relapsing
NMOSD-like phenotype, or RON as final diagnosis [13,41,42].
In 2012, a study reported that a proportion of MOG-ab-positive
children with ON will experience further relapse(s), and suggested
that these patients represent a separate subgroup distinct fromMS
or NMOSD [19]. Subsequently, several studies confirmed that pae-
diatric MOG-ON patients show higher rates of recurrence
compared to paediatric MOG-ab-negative [36,38] and MS patients
with ON [48]. These relapses have been shown to be highly steroid-
responsive, or even steroid-dependent. Therefore, relapsing MOG-
ab-positive patients often meet criteria for chronic relapsing in-
flammatory optic neuropathy (CRION) [41,53,86,87].
Compared to other paediatric relapsing MOGAD, RON patients
had a similar number of relapses, but a slightly longer time to their
first relapse, and more often a good outcome, defined as expanded
disability status scale (EDSS) score of 0 [82,123].
4.4. Relapsing NMOSD-like phenotype
Patients who present with an NMOSD-like phenotype at onset
of disease can experience further relapses during disease course,
mainly ON or simultaneous ON and (LE)TM [82]. Furthermore, also
patients initially presenting with isolated ON or (LE)TM may have
subsequent relapse(s), converting to a relapsing NMOSD-like
phenotype during follow-up [32]. Finally, some patients present-
ing with ADEM also convert to this phenotype due to further re-
lapses with for example simultaneous ON and (LE)TM, or sequential
relapses with ON as well as (LE)TM [12,21,33,82].
From all paediatric patients with NMOSD (fulfilling Wingerchuk
diagnostic criteria [64]) or limited forms of NMOSD (including
LETM, bilateral ON, brainstem syndromes or RON), only half of the
MOG-ab-positive patients relapsed, compared to 100% of AQP4-ab-
positive patients [32]. While adult studies have shown better
outcome in MOG-ab-positive than AQP4-ab-positive patients [38],
no differences in outcome between these groups in paediatric pa-
tients were observed regarding VA and EDSS, possibly due to
limited number of AQP4-ab-positive patients included in this study
(n ¼ 5), related to the rarity in childhood [32].
5. Emerging and atypical clinical phenotypes
Due to the continuing research in this field, MOG-abs are
consistently identified within new disease presentations, thus
expanding the spectrum of MOGAD. These disease presentations
are overall rare and include less common or atypical demyelinating
phenotypes, and phenotypes beyond the demyelinating
syndromes.
5.1. Encephalitis, overlapping syndromes and seizures
A number of case series [88e95] and retrospective studies
[97e99] have reported an association between MOG-abs and en-
cephalitis, mainly in adult, but also more recently in paediatric
patients [99]. ADEM and encephalitis are both characterised by
encephalopathy. However, ADEM typically includes demyelinating
features with clinically ON and/or TM, and on neuroimaging poorly
demarcatedwidespread lesions of predominantly whitematter and
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cortical lesions or no abnormalities at all [2,102,102]. The reported
(mainly adult) patients with encephalitis and MOG-abs presented
with seizures, headache and/or fever, with uni- or bilateral cortical
lesions on brain MRI, also referred to as “cortical encephalitis”
[89e99].
Recently, this association between MOG-abs and encephalitis
has been explored further in two paediatric studies [24,103],
including one large prospective, multicentre, observational paedi-
atric cohort study from Spain [23]. In this study, among the 296
patients with definite or possible encephalitis (according to inter-
national criteria [103]), 7% had MOG-abs [23]. Even more inter-
esting, among the 64 patients with autoimmune encephalitis (AE,
excluding encephalitis patients with an infectious or unknown
cause), 34% of patients had MOG-abs, which was more common
than all neuronal antibodies combined (33%; 22% had N-methyl-D-
aspartate-receptor (NMDAR)-abs). MOG-ab-positive patients with
encephalitis clinically showed impaired consciousness (100%),
seizures (64%; 45% with status epilepticus), fever (59%), and
abnormal behaviour (50%) and movements (36%). Brain MRI
showed cortical involvement in 73% of patients, which was exten-
sive and bilateral in most of these patients (75%), and additional or
isolated basal ganglia or thalamic involvement in 41% of patients.
Only 9% of these patients had no radiological abnormalities, which
is clearly lower than reported for other forms of AE, e.g. in anti-
NMDAR encephalitis, 55% of patients had a normal MRI [103].
Within a median follow-up of 42 months, 23% of MOG-ab-positive
patients with encephalitis had further relapses, including a demy-
elinating syndrome (ON or TM) in 80% of these relapsing patients
[22]. This is in line with above-mentioned case reports and retro-
spective studies reporting MOG-ab-positive patients with en-
cephalitis, in which patients frequently, but not always,
experienced prior, accompanying or subsequent clinical and/or
radiological demyelinating events beside the cortical encephalitis
event(s) [88,89,91e93,95e98,101].
Whether MOG-abs are the causative agent of the encephalitis
and cortical lesions remains to be determined. Only a few studies
reported additional pathological findings in these patients, which
are inconsistent. The brain autopsy of one deceased patient showed
multiple predominantly cortical demyelinating lesions [90], while
evidence for demyelination was absent in the brain biopsies of two
other cases [89,92]. This absence of demyelination could be due to
the biopsy taken in the very early stage of disease, before fulminant
demyelination [92]. However, it could also suggest that another
autoantibody is responsible for the encephalitis and may coexist
with MOG-abs [90,97], which in its turn is responsible for the
additional demyelinating features in the majority of these patients.
Such overlapping syndromes with MOG-abs and other autoanti-
bodies have been described, mainly in patients with anti-NMDAR
encephalitis, both in adult [105e110] and paediatric patients
[102,105,107,111e113]. These patients had either concurrent or
separate episodes compatible with anti-NMDAR encephalitis
(mainly clinically) or MOGAD (mainly radiologically) [113], and had
more relapses compared to anti-NMDAR encephalitis patients
without MOG-abs [111,112]. Additionally, an overlapping syndrome
with MOG-abs and Glycine receptor antibodies has also been
described in a limited number of paediatric patients [23].
Although seizures most often occur during an encephalitis
episode (including ADEM, cortical encephalitis or overlap syn-
drome with anti-NMDAR encephalitis), isolated seizures have been
described in both adult and paediatric MOG-ab-positive patients
[41,114,115]. These patients had an unremarkable brain MRI at
onset, but all developed typical demyelinating events with MRI
abnormalities during follow-up, with persisting MOG-abs.8
Although the interval between the isolated seizures and a new
demyelinating event ranged from months to years, these subse-
quent demyelinating events are suggestive of an underlying
immunological pathogenesis that was potentially already present
at onset of the isolated seizures [114]. Although no inflammatory
involvement of the cortex was observed in any of these patients
during onset, such cortical lesions could have been missed with
regular brain MRI. If indeed an immunological pathogenesis un-
derlies these seizures, this may have important treatment impli-
cations. Importantly, isolated seizures after an encephalitis episode
will not always represent new inflammatory activity but can also be
the result of cortical damage from the initial episode.
Altogether, although the underlying pathophysiology has not
been fully elucidated yet, MOG-abs are found in a significant subset
of paediatric patients presenting with AE other than ADEM,
expanding the spectrum of MOGAD. These patients often have
seizures and primarily cortical involvement on MRI in the pre-
senting event. Most of these patients also have clinical and/or
radiological features of demyelination, either simultaneously or
subsequently, which is relevant for clinical management.
5.2. Leukodystrophy-like phenotype
Most MOG-ab-positive patients presenting with ADEM have
large, diffuse, poorly demarcated, bilateral, but asymmetrical white
matter changes on MRI, which often dramatically resolve during
follow-up, concurrently with an overall good recovery [30]. How-
ever, some MOG-ab-positive patients presenting with ADEM
exhibit a more symmetrical extensive confluent pattern on MRI
that progresses over time, which resembles a genetic or metabolic
leukodystrophy, but with no indication for such underlying dis-
eases in extensive additional testing [23,82,116]. A retrospective
study further analysed this subgroup of patients and found seven
patients who developed a leukodystrophy-like pattern on MRI
within a cohort of 31 paediatric MOG-ab-positive patients [118].
This leukodystrophy-like phenotype was only seen in patients
younger than seven years old, and more frequently observed in the
youngest patients (mean age 3.7 years), compared to the middle-
age group (mean age 5.2 years) who more often had ADEM-like
lesions. All patients with a leukodystrophy-like MRI pattern were
diagnosed with ADEM at onset of disease and presented either at
onset or at relapse with encephalopathy (100%), ataxia (100%), ON
(71%), and/or seizures (43%). While all these patients did show
clinical improvement after acute treatment with steroids, their
overall outcomewas poor, and, importantly, worse compared to the
patients without this leukodystrophy-like pattern on MRI (EDSS 3
vs. 0). In addition, persistent cognitive and behavioural problems
were observed in 57%, and ongoing seizures in 43% of patients. In
total, 40% of patients continued to have relapses despite treatment
with disease-modifying drugs, or only showed a partial response to
second-line immunotherapy. Yet, the total number of relapses did
not differ from the other MOG-ab-positive patients in their cohort.
Additionally, this leukodystrophy-like MRI pattern has also been
associated with a poor outcome in the above mentioned large
prospective study from Spain [23].
This overall very rare phenotype fits in the age-dependency of
MOGAD, with more ADEM-like presentations in the younger pae-
diatric patients, and even more extensive brain involvement with
such leukodystrophy-like phenotypes in the youngest MOG-ab-
positive population.
5.3. Combined central and peripheral demyelination in MOGAD
A few MOG-ab-positive cases are reported with central as well
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tients reported had peripheral cranial nerve involvement together
with accompanying brain lesions with or without encephalopathy
[118], or a polyradiculoneuropathy simultaneously with TM [119].
These phenotypes can be referred to as “brain plus phenotype” or
“TM plus phenotype”, respectively. Although MOG is thought to be
CNS specific, peripheral MOG has been identified in rats and pri-
mates as well [120]. Nevertheless, further investigation in humans
is needed to determine whether MOG-abs are the causative agent
in these reported “plus” phenotypes.5.4. Non-classifiable clinical phenotypes
Previous studies have also reported several MOG-ab-associated
atypical monophasic or recurrent syndromes, which did not fulfil
any of the current criteria within the ADS or encephalitis spectrum
[23,41]. These comprised for example patients with the above-
mentioned combination of encephalitis and following demyelin-
ating features, or patients with other syndromes without enceph-
alopathy and ADEM-like lesions on MRI or MRI lesions not
resembling ADEM of MS. These non-classifiable clinical phenotypes
underline the need for an updated MOGAD terminology.6. Conclusion
This review emphasises the diversity in clinical phenotypes
associated with MOG-abs in paediatric patients. The majority of
MOGAD presentations consist of demyelinating syndromes,
including typical phenotypes as ADEM in younger, and ON and/or
TM in older children. A proportion of patients experience aFig. 3. Paediatric European Collaborative Consensus recommendation on MOG-ab testing (
# Up to 90% of paediatric-onset MS patients have OCB specific to the CSF [122].
* A minor proportion of paediatric-onset MS patients have MOG-abs (mostly low titre/weak
MOG-abs should result in patient referral to a centre of expertise for further management.
AQP4-ab ¼ aquaporin-4 antibody, CBA ¼ cell-based assay, CSF ¼ cerebrospinal fluid, NM
glycoprotein antibody, MOGAD ¼ MOG-ab-associated disorders, MRI ¼ magnetic resonance
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relapsing disease course, presenting as ADEM-ON, MDEM, RON or
relapsing NMOSD-like syndromes. More recently, the disease
spectrum has been expanded to include (recurrent) encephalitis-
like, overlapping syndromes, leukodystrophy-like, and non-
classifiable phenotypes.7. Expert consensus recommendations
Presence of MOG-abs has consequences due to the relapse risk
and possible treatment interventions [125], and for accurate
counselling of patient and families. Based on the wide diversity of
paediatric MOGAD, and the fact that MOG-abs are common in
childhood, we recommend to test all paediatric patients presenting
with a demyelinating or encephalitic event with abnormalities on
brain and/or spinal MRI (Fig. 3). This MOG-ab testing should be
combined with AQP4-ab testing in the blood, and with CSF analysis
for oligoclonal bands (OCB). Previous suggested protocols of MOG-
ab testing advised to only test for MOG-abs in atypical MS pre-
sentations [81,120]. However, in our opinion, the interpretation of
typical MS can differ between clinicians. MOG-ab positivity should
result in patient referral to a centre of expertise for further man-
agement. Additionally, previously suggested protocols advised to
only test NMOSD patients for MOG-abs if they were tested negative
for AQP4-abs [82,120]. As in childhood MOG-abs are found five
times more often than AQP4-abs, especially in patients presenting
with simultaneous ON and (LE)TM, patients with an NMOSD-like
phenotype need to be tested at onset for both MOG-abs and
AQP4-abs. Finally, in patients with encephalitic syndromes with
abnormalities on brain and/or spinal MRI, MOG-ab testing should
be included in the initial work-up, as in these patients MOG-abs arein an accredited laboratory) in paediatric patients.
positive CBA test result which rapidly declines during follow-up). However, presence of
OSD ¼ neuromyelitis optica spectrum disorders, MOG-ab ¼ myelin oligodendrocyte
imaging, MS ¼ multiple sclerosis, OCB ¼ oligoclonal bands, þ ¼ positive, e ¼ negative.
Table 2
Clinical classification of paediatric MOGAD with corresponding key features.
Disease course Classification Key features
Monophasic MOGAD
with
ADEM phenotype Younger patients
Characterised by encephalopathy
Often longitudinal spinal cord involvement, which can be asymptomatic
ON phenotype Adolescents
Severe vision loss at onset, anterior and bilateral optic nerve involvement, with disc oedema
Overall good and often rapid functional recovery, but indication of permanent axonal damage (OCT)
ON plus phenotype ON and optic perineuritis (perineural enhancement and inflammation of orbital tissues)
TM phenotype Adolescents
Severe motor and sensory deficits at onset; subset with conus involvement and following bladder problems
Overall good and often rapid motor recovery, but bowel/bladder residual symptoms are common
NMOSD-like phenotype Adolescents
Simultaneous ON and TM
encephalitis-like phenotype Seizures and cortical lesions, with adjacent subcortical involvement in a subset of patients
Relapsing* MOGAD with ADEM-ON phenotype Younger patients
Recurrent episode(s) of ON more than 3 months after start of previous ADEM episode
MDEM phenotype Younger patients
Characterised by encephalopathy
Recurrent episode(s) of ADEM more than 3 months after start of previous ADEM episode
RON phenotype Adolescents
Relapsing ON episodes, often steroid responsive, sometimes steroid-dependent
NMOSD-like phenotype Adolescents
ON followed by subsequent TM or reversed; or simultaneous ON and TM followed by new ON and/or TM
episode(s)
encephalitis-like phenotype Seizures and cortical lesions, with adjacent subcortical involvement in a subset of patients
Subsequently with demyelinating event(s)/lesion(s)
leukodystrophy-like
phenotype
Youngest patients
Encephalopathy, ataxia, ON and/or seizures
Extensive brain involvement
* A relapse is defined by the consensus group as a new clinical episode accompanied by radiological evidence depending on the subtype of MOGAD, appearing at least one
month subsequently to the last acute attack, while a ‘flare-up’ is defined as re-occurrence of symptomswithin onemonth (and up to threemonths in ADEMpatients) after start
of acute treatment and not meeting definition of a relapse [125].
ADEM ¼ acute disseminated encephalomyelitis, ADEM-ON ¼ ADEM episode followed by one of more optic neuritis episode(s), MDEM ¼ multiphasic disseminated
encephalomyelitis, MOGAD ¼ MOG-ab-associated disorders, OCT ¼ optical coherence tomography, ON ¼ optic neuritis, TM ¼ transverse myelitis, RON ¼ relapsing optic
neuritis.
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Due to challenges in MOG-ab laboratory testing, it is of utmost
importance that MOG-abs are tested only in an accredited labora-
tory, in order to avoid false positive or false negative test results
[10].
MOGAD phenotypes can change during follow-up, depending
on age at onset and possible relapses during follow-up. Therefore,
MOGAD presents a fluid disease spectrum compared to the more
defined AQP4-ab-positive NMOSD. Accordingly, and besides the
already mentioned additional clinical and immunological differ-
ences, we believe MOGAD and AQP4-ab-positive NMOSD are
distinctive demyelinating disorders of the CNS and should be
classified as two different disease entities. We here suggest using
an antibody-directed classification, with use of the term MOGAD
for all MOG-ab-positive patients, with subsequent addition of the
disease course (monophasic vs. relapsing) and their clinical
phenotype: e.g. monophasic or relapsing MOGAD with ADEM
phenotype; with NMOSD-like phenotype; with encephalitis-like
phenotype; or with non-classifiable phenotype. This proposed
clinical classification of paediatric MOGAD with corresponding key
features is shown in Table 2. This classification is operational and
needs to be tested, but importantly, the potentially changing
MOGAD phenotype during disease course can also be appointed
with this classification, which is essential to incorporate in future
paediatric MOGAD studies.10Funding sources
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